Commercial Fully Automated Procalcitonin Immunoassay Compared
By LabMedica International staff writers Posted on 04 Dec 2018 |
Image: The ARCHITECT B.R.A.H.M.S PCT assay, which is a two-step immunoassay using chemiluminescent microparticle immunoassay (CMIA) technology (Photo courtesy of Abbott Laboratories).
Procalcitonin (PCT), a 13-kDa peptide precursor of calcitonin, has gained widespread acceptance as an early and specific biomarker for the presence of systemic bacterial infection. In particular, PCT monitoring has demonstrated value in guiding antibiotic use for bacterial infections.
Based on high plasma levels of PCT during systemic bacterial and fungal infections that decrease on recovery and low concentrations during infections of viral origin or nonspecific causes, the use of PCT assays can be used to assist the clinical management of different patient groups in a range of clinical settings.
An international team of scientists working with the Abbott Laboratories (Abbott Park, IL, USA) using de-identified 1,116 plasma or serum samples from patients tested at nine clinical laboratories in Australia, France, Germany, Italy, South Africa, Turkey, Vietnam and Wales. Plasma or serum samples were tested either fresh or following storage of the serum fraction at 2–8 °C for a maximum of 24 hours.
The team evaluated the ARCHITECT B.R.A.H.M.S PCT assay, which is a two-step immunoassay using chemiluminescent microparticle immunoassay (CMIA) technology, with a 29-minute assay completion time. The ARCHITECT B.R.A.H.M.S PCT assay was evaluated on Abbott Laboratories’ ARCHITECT i2000SR immunoanalyzers. The ARCHITECT B.R.A.H.M.S PCT assay was compared with the Roche Cobas (Basel, Switzerland), Diasorin LIAISON (Saluggia, Italy); bioMérieux VIDAS (Marcy-l'Étoile, France), and widely accepted B.R.A.H.M.S Kryptor systems (Hennigsdorf, Germany).
The scientists reported that using Deming regression analysis of the plasma or serum samples with PCT results detected across a dynamic assay range of 0.02–100 μg/L using the ARCHITECT B.R.A.H.M.S PCT assay yielded results of r = 0.989 versus. Roche Cobas, r = 0.986 versus Kryptor B.R.A.H.M.S, r = 0.987 versus BioMérieux VIDAS and r = 0.972 versus Diasorin LIAISON respectively. Concordance at cut-offs of 0.25 μg/L and 0.50 μg/L were 96.9% and 98.1% with Roche Cobas, 95.4% and 96.1% with B.R.A.H.M.S Kryptor, 93.8% and 98.4% with bioMérieux VIDAS, and 92.7% and 93.9% with Diasorin LIAISON.
The authors concluded that independent observations at nine different clinical laboratory sites confirmed the analytical characteristics of the ARCHITECT B.R.A.H.M.S PCT immunoassay. Compared with other assays, ARCHITECT B.R.A.H.M.S PCT offers excellent precision and low-end sensitivity. The study was published on November 9, 2018, in the journal Practical Laboratory Medicine.
Based on high plasma levels of PCT during systemic bacterial and fungal infections that decrease on recovery and low concentrations during infections of viral origin or nonspecific causes, the use of PCT assays can be used to assist the clinical management of different patient groups in a range of clinical settings.
An international team of scientists working with the Abbott Laboratories (Abbott Park, IL, USA) using de-identified 1,116 plasma or serum samples from patients tested at nine clinical laboratories in Australia, France, Germany, Italy, South Africa, Turkey, Vietnam and Wales. Plasma or serum samples were tested either fresh or following storage of the serum fraction at 2–8 °C for a maximum of 24 hours.
The team evaluated the ARCHITECT B.R.A.H.M.S PCT assay, which is a two-step immunoassay using chemiluminescent microparticle immunoassay (CMIA) technology, with a 29-minute assay completion time. The ARCHITECT B.R.A.H.M.S PCT assay was evaluated on Abbott Laboratories’ ARCHITECT i2000SR immunoanalyzers. The ARCHITECT B.R.A.H.M.S PCT assay was compared with the Roche Cobas (Basel, Switzerland), Diasorin LIAISON (Saluggia, Italy); bioMérieux VIDAS (Marcy-l'Étoile, France), and widely accepted B.R.A.H.M.S Kryptor systems (Hennigsdorf, Germany).
The scientists reported that using Deming regression analysis of the plasma or serum samples with PCT results detected across a dynamic assay range of 0.02–100 μg/L using the ARCHITECT B.R.A.H.M.S PCT assay yielded results of r = 0.989 versus. Roche Cobas, r = 0.986 versus Kryptor B.R.A.H.M.S, r = 0.987 versus BioMérieux VIDAS and r = 0.972 versus Diasorin LIAISON respectively. Concordance at cut-offs of 0.25 μg/L and 0.50 μg/L were 96.9% and 98.1% with Roche Cobas, 95.4% and 96.1% with B.R.A.H.M.S Kryptor, 93.8% and 98.4% with bioMérieux VIDAS, and 92.7% and 93.9% with Diasorin LIAISON.
The authors concluded that independent observations at nine different clinical laboratory sites confirmed the analytical characteristics of the ARCHITECT B.R.A.H.M.S PCT immunoassay. Compared with other assays, ARCHITECT B.R.A.H.M.S PCT offers excellent precision and low-end sensitivity. The study was published on November 9, 2018, in the journal Practical Laboratory Medicine.
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms